Regulators and clinicians discuss ethics, long‑term monitoring and access after FDA okay for sickle cell gene therapies
Loading...
Summary
HHS and expert panelists outlined institutional responsibilities for human research, regulatory expectations for long‑term safety monitoring and challenges making costly, newly approved gene therapies accessible to Medicaid patients and communities with limited specialist access.
Federal and clinical experts at an OHRP webinar laid out ethical, regulatory and implementation challenges as gene therapies for sickle cell disease reach clinical use.
Captain David Wong, senior advisor at HHS's Office for Human Research Protections, framed the session by noting federal coordination efforts — the Sickle Cell Disease Federal Agency work group, NIH research programs including the Cure Sickle Cell Initiative, and HRSA treatment demonstrations — and said the Food and Drug Administration approved two milestone gene therapies in December 2023 for people 12 years and older.
"OHRP is celebrating its 25th anniversary this year and is responsible for providing leadership in the protection of the rights, welfare, and well‑being of human subjects involved in research conducted or supported by HHS," Wong said while introducing the webinar’s ethics theme.
Dr. Willie Smith (Florence Neal Cooper Smith Professorship, Virginia Commonwealth University) emphasized the institutional obligation "to do no harm" and the duty to explain risks and benefits clearly to patients and families. He said protocols must specify inclusion and exclusion criteria, anticipated risks and the scientific rationale for them. Smith noted that sponsors and institutions commonly expect long‑term follow up after administration of gene therapies: "Imagine being a company and being told after you have given your therapy, you need to follow your patient for 15 years," he said, explaining the need to monitor for late adverse events and long‑term benefits.
Dr. Krishnamoorthi (chief, pediatric hematology, Yale School of Medicine) and other panelists discussed trust and access. Krishnamoorthi said many patients never learn that curative or transformative options exist because they receive episodic care in emergency settings rather than specialist clinics. He argued for outreach beyond the clinic and for multiple shared‑decision conversations: "You ought to be sitting down with a doctor that knows about gene therapy and just have a conversation," he said.
On affordability and coverage, panelists pointed to federal implementation work. Krishnamoorthi said CMS has negotiated a cell and gene therapy access model that now involves 33 states plus the District of Columbia and Puerto Rico and that state Medicaid programs are interpreting coverage responsibilities. He paraphrased a Connecticut official: "FDA has approved this treatment. Medicaid must pay," while noting coverage implementation and family support logistics remain complex.
From the FDA perspective, Dr. Megha Kaushal (branch chief, benign hematology, CBER) described the agency's review priorities: robust clinical endpoints showing clinical benefit (for example, reductions in vaso‑occlusive crises), extensive safety evaluation, and planning for long‑term adverse‑event collection after authorization. She said the agency advised sponsors on trial end points and safety monitoring during development and continues to review adverse‑event data in post‑market follow up.
Panelists also discussed practical access limits: the panel cited roughly "40 or 50" qualified treatment centers for some products and noted that for one product there are about 51 centers and for another "40 plus". They urged clinicians who lack expertise to connect with specialist centers or national resources such as the National Alliance for Sickle Cell Centers (NASEC) so patients can learn whether they might benefit.
On psychosocial issues, speakers said quality‑of‑life measures often improve after transformative therapy, but patients also face identity and mental‑health transitions when a long‑term illness recedes. Panelists called for implementation planning that includes family support, childcare, and psychosocial services alongside medical care.
The webinar concluded with a call to continue outreach, community engagement and provider education; organizers encouraged attendance at a second session hosted by HHS's Office of Minority Health and said materials would be archived online.
